Free Trial

Oncolytics Biotech (TSE:ONC) Stock Price Up 24.1% - Should You Buy?

Oncolytics Biotech logo with Medical background

Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) were up 24.1% during trading on Wednesday . The company traded as high as C$1.72 and last traded at C$1.70. Approximately 892,106 shares changed hands during mid-day trading, an increase of 556% from the average daily volume of 135,968 shares. The stock had previously closed at C$1.37.

Analysts Set New Price Targets

Separately, Jones Trading lowered Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.

Read Our Latest Research Report on Oncolytics Biotech

Oncolytics Biotech Stock Performance

The stock has a 50-day moving average of C$0.82 and a 200 day moving average of C$0.94. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock has a market capitalization of C$123.32 million, a price-to-earnings ratio of -4.46 and a beta of 1.35.

About Oncolytics Biotech

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Further Reading

Should You Invest $1,000 in Oncolytics Biotech Right Now?

Before you consider Oncolytics Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.

While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines